These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31737505)

  • 61. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins).
    Eberlein M; Heusinger-Ribeiro J; Goppelt-Struebe M
    Br J Pharmacol; 2001 Aug; 133(7):1172-80. PubMed ID: 11487529
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c.
    Ghavami S; Mutawe MM; Hauff K; Stelmack GL; Schaafsma D; Sharma P; McNeill KD; Hynes TS; Kung SK; Unruh H; Klonisch T; Hatch GM; Los M; Halayko AJ
    Biochim Biophys Acta; 2010 Apr; 1803(4):452-67. PubMed ID: 20045437
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The sensitivity of head and neck carcinoma cells to statins is related to the expression of their Ras expression status, and statin-induced apoptosis is mediated via suppression of the Ras/ERK and Ras/mTOR pathways.
    Tsubaki M; Fujiwara D; Takeda T; Kino T; Tomonari Y; Itoh T; Imano M; Satou T; Sakaguchi K; Nishida S
    Clin Exp Pharmacol Physiol; 2017 Feb; 44(2):222-234. PubMed ID: 27805296
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment.
    Chimento A; Casaburi I; Avena P; Trotta F; De Luca A; Rago V; Pezzi V; Sirianni R
    Front Endocrinol (Lausanne); 2018; 9():807. PubMed ID: 30719023
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins.
    Shiomi M; Koike T; Ito T
    Atherosclerosis; 2013 Nov; 231(1):39-47. PubMed ID: 24125408
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prevention of Hepatocellular Carcinoma by Statins: Clinical Evidence and Plausible Mechanisms.
    Kim G; Kang ES
    Semin Liver Dis; 2019 May; 39(2):141-152. PubMed ID: 30912095
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) pathway regulates developmental cerebral-vascular stability via prenylation-dependent signalling pathway.
    Eisa-Beygi S; Hatch G; Noble S; Ekker M; Moon TW
    Dev Biol; 2013 Jan; 373(2):258-66. PubMed ID: 23206891
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Statins inhibited the MIP-1α expression via inhibition of Ras/ERK and Ras/Akt pathways in myeloma cells.
    Tsubaki M; Mashimo K; Takeda T; Kino T; Fujita A; Itoh T; Imano M; Sakaguchi K; Satou T; Nishida S
    Biomed Pharmacother; 2016 Mar; 78():23-29. PubMed ID: 26898421
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Statin-Induced Cancer Cell Death Can Be Mechanistically Uncoupled from Prenylation of RAS Family Proteins.
    Yu R; Longo J; van Leeuwen JE; Mullen PJ; Ba-Alawi W; Haibe-Kains B; Penn LZ
    Cancer Res; 2018 Mar; 78(5):1347-1357. PubMed ID: 29229608
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors.
    Kubota T; Fujisaki K; Itoh Y; Yano T; Sendo T; Oishi R
    Biochem Pharmacol; 2004 Jun; 67(12):2175-86. PubMed ID: 15163549
    [TBL] [Abstract][Full Text] [Related]  

  • 71. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways.
    Rupérez M; Rodrigues-Díez R; Blanco-Colio LM; Sánchez-López E; Rodríguez-Vita J; Esteban V; Carvajal G; Plaza JJ; Egido J; Ruiz-Ortega M
    Hypertension; 2007 Aug; 50(2):377-83. PubMed ID: 17592071
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Statins, stem cells, and cancer.
    Gauthaman K; Fong CY; Bongso A
    J Cell Biochem; 2009 Apr; 106(6):975-83. PubMed ID: 19224538
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Statin use and cancer risk: an epidemiologic review.
    Friis S; Olsen JH
    Cancer Invest; 2006; 24(4):413-24. PubMed ID: 16777695
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved.
    Tristano AG; Fuller K
    Int Immunopharmacol; 2006 Dec; 6(12):1833-46. PubMed ID: 17052674
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
    Evans M; Rees A
    Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy.
    Pereira M; Matuszewska K; Glogova A; Petrik J
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884561
    [TBL] [Abstract][Full Text] [Related]  

  • 77. STATINS AND BONE HEALTH: A MINI REVIEW.
    Morse LR; Coker J; Battaglino RA
    Actual osteol; 2018; 14(1):31-35. PubMed ID: 30237809
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Statins inhibit proliferation and cytotoxicity of a human leukemic natural killer cell line.
    Crosbie J; Magnussen M; Dornbier R; Iannone A; Steele TA
    Biomark Res; 2013 Dec; 1(1):33. PubMed ID: 24359683
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role.
    Marcianò G; Palleria C; Casarella A; Rania V; Basile E; Catarisano L; Vocca C; Bianco L; Pelaia C; Cione E; D'Agostino B; Citraro R; De Sarro G; Gallelli L
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631415
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Novel Uses for Lipid-Lowering Agents.
    May MB; Glode A
    J Adv Pract Oncol; 2016 Mar; 7(2):181-187. PubMed ID: 28090367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.